| Title: |
Analysis of Patients with Focal Epilepsy and Drug-Resistant Epilepsy in Italy: Evaluation of Their Characteristics, Therapeutic Pathway and the Consumption of Healthcare Resources |
| Authors: |
Perrone V.; Veronesi C.; Dovizio M.; Ancona D. D.; Andretta M.; Bartolini F.; Cavaliere A.; Chinellato A.; Ciaccia A.; Cillo M.; De Francesco A.; Enieri N.; Ferrante F.; Gentile S.; Procacci C.; Ubertazzo L.; Vercellone A.; Lucatelli D.; Procaccini M.; Esposti L. D. |
| Contributors: |
Perrone, V.; Veronesi, C.; Dovizio, M.; Ancona, D. D.; Andretta, M.; Bartolini, F.; Cavaliere, A.; Chinellato, A.; Ciaccia, A.; Cillo, M.; De Francesco, A.; Enieri, N.; Ferrante, F.; Gentile, S.; Procacci, C.; Ubertazzo, L.; Vercellone, A.; Lucatelli, D.; Procaccini, M.; Esposti, L. D. |
| Publication Year: |
2022 |
| Collection: |
ARUd'A - Archivio Istituzionale della ricerca dell'università Chieti-Pescara (IRIS) |
| Subject Terms: |
clinical practice; epilepsy; healthcare resource consumption; pharmacoutilization; real-world evidence |
| Description: |
Purpose: A retrospective analysis was conducted to estimate the number of patients with focal epilepsy and drug-resistant epilepsy (DRE) and their characteristics, the therapeutic patterns, the consumption of health resources in a real-world Italian setting. Patients and Methods: A retrospective study was carried out on the administrative databases of a sample of Italian Health Departments, covering approximately 8.7 million health-assisted individuals. All adult patients with at least one hospitalization for focal epilepsy and an electroencephalogram (between 01/2010 and 12/2019), and at least one prescription of antiseizure medication (ASM) (between 01/2011 and 12/2018) were included in the study. Patients with at least two treatment failures and treated with a subsequent ASM were considered DRE.Results: Overall, 1897 patients with focal epilepsy (mean age 56 years, 47% male) were identified, of which 485 (25.6%) with DRE (mean age 53 years, 43% male). Among patients with focal epilepsy and DRE, respectively, 48% and 54% had essential hypertension, 23.4% and 26.6% had cardiovascular disease, and 46.3% and 62.1% had peptic ulcer/prescription of gastric secretion inhibitors. During follow-up, patients with focal epilepsy maintained first-line treatment for 53.9 months; among these, 52% passed to the second-line, and 485 (25.6% of the total) began third-line treatment. In patients with focal epilepsy, the mean cost was euro 4448 (of which euro 1410 were epilepsy-related), and in DRE patients total expenditures averages euro 5825 (of which euro 2165 were epilepsy-related). In both patients with focal epilepsy and DRE, hospitalizations represented the most impacting item of expenditure.Conclusion: The present analysis conducted in a setting of Italian clinical practice has shown that 25% of patients with focal epilepsy were resistant to antiepileptic treatments. Furthermore, these results showed that health-care costs for the management of epileptic patients were mainly accountable for the costs related to the ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/35923519; info:eu-repo/semantics/altIdentifier/wos/WOS:000836311000001; volume:14; firstpage:513; lastpage:521; numberofpages:9; journal:CLINICOECONOMICS AND OUTCOMES RESEARCH; https://hdl.handle.net/11564/828836 |
| DOI: |
10.2147/CEOR.S361692 |
| Availability: |
https://hdl.handle.net/11564/828836; https://doi.org/10.2147/CEOR.S361692 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.C43E3AF3 |
| Database: |
BASE |